The unmasked CD44×PD‐L1/CD3 trispecific T‐cell nanoengager (TriTNE) targets dual tumor‐associated antigens (TAAs) to redirect CD8+ T cells for heterogeneous TNBC lysis while achieving PD‐L1 blockade. This evidence concerns the gene CD8A and neoplasm.